Concourse Financial Group Securities, Inc. Erasca, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.56 Billion
- Q2 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ERAS
# of Institutions
133Shares Held
205MCall Options Held
3.1KPut Options Held
142K-
Frazier Life Sciences Management, L.P. Menlo Park, CA16.2MShares$46.9 Million2.26% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$46.9 Million4.2% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$39.8 Million1.36% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$32 Million15.29% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$30.7 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $353M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...